Clinical Pearls for Early Career Success: Proceedings from The 2018 Retina Fellow Summit
These activities provide retina fellows and retina specialists with education that addresses the latest clinical data, translational research, and pearls for transitioning from fellowship.
Click Below for Faculty Introductions
This activity has been designed to meet the educational needs of retina fellows, ophthalmology residents, retina specialists, and comprehensive ophthalmologists who treat diseases of the retina.
Upon completion of this activity, participants will be better able to do the following:
- Evaluate and interpret the expanding literature regarding treatment of retinal vascular diseases.
- Develop optimal, individualized management plans by applying the latest clinical data.
- Describe considerations in making transitions to practice.
- Discuss practical aspects of achieving success in practice.
Diana V. Do, MD, FAAO (Course Director)
Quan Dong Nguyen, MD, MSc, FAAO (Course Director)
Robert Bhisitkul, MD, PhD
Peter K. Kaiser, MD
Jonathan L. Prenner, MD
Christina Y. Weng, MD, MBA
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
|Faculty||Relationship Identified With:|
|Diana V. Do, MD, FAAO|
Research Support: BioTime, Genentech, Regeneron, SantenScientific Advisory Board: Allergan, Clearside, Genentech, Kodiak, Regeneron
Quan Dong Nguyen, MD, MSc, FAAO
Research Support: Gilead, Genentech, KalVista, Regeneron, Santen
Scientific Advisory Board: EyePoint, Gilead, Genentech, Regeneron, Santen
|Robert Bhisitkul, MD, PhD|
Consultant/Advisor: Ribomic, Inc, Quark, AntriaBio
Grant/Research Support: Genentech
Stock Ownership: Zordera Co-Founder
|Peter K. Kaiser, MD||Consultant/Advisor: Aerie, Aerpio, Alcon, Allegro, Allergan, Bayer, Bausch and Lomb|
|Jonathan L. Prenner, MD||Consultant/Advisor: Alcon|
|Christina Y. Weng, MD, MBA||Consultant/Advisor: Allergan, Alimera Sciences, Inc|
Non-faculty: Alison Kemp, Bernard M. Abrams, MD, Louis Settembrino, CHCP, and Christina M. Ohnsman, MD, hereby state that neither they nor their spouse/life partner have had any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
This activity has been supported by an independent educational grant from Regeneron Pharmaceuticals Inc.
Jointly provided by the Elsevier Office of Continuing Medical Education and Catalyst Medical Education, LLC.
CME Credit (Physicians)
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Catalyst Medical Education, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CME INQUIRIES/SPECIAL NEEDS
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Catalyst Medical Education, LLC., and Regeneron Pharmaceuticals Inc. do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 1.50 AMA PRA Category 1 Credit(s)™
- 1.50 Non-physician